$CVS
CVS Health Corp Stock $cvs

$cvs Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000006480322000008 Filed on February 09, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$76.60B	$292.1B	$69.55B
YoY Change	10.14%	8.71%	3.98%
Cost Of Revenue	$46.38B	$175.8B	$42.45B
YoY Change	9.25%	7.21%	0.92%
Gross Profit	$30.23B	$116.3B	$27.10B
YoY Change	11.53%	11.06%	9.18%
Gross Profit Margin	39.46%	39.82%	38.97%
Selling, General & Admin		$523.0M	$9.295B
YoY Change		-98.51%	10.73%
% of Gross Profit		0.45%	34.3%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$4.512B
YoY Change		1.6%
% of Gross Profit		3.88%
Operating Expenses	$26.61B	$101.2B	$24.44B
YoY Change	8.87%	11.51%	13.53%
Operating Profit	$3.618B	$13.19B	$2.662B
YoY Change	35.91%	-5.16%	-12.35%
Interest Expense	-$608.0M	$2.503B	-$678.0M
YoY Change	-10.32%	-13.9%	-7.63%
% of Operating Profit	-16.8%	18.97%	-25.47%
Other Income/Expense, Net	$38.00M	$182.0M	$53.00M
YoY Change	-28.3%	-11.65%	70.97%
Pretax Income	$1.570B	$10.42B	$1.225B
YoY Change	28.16%	6.65%	-47.51%
Income Tax	$274.0M	$2.522B	$241.0M
% Of Pretax Income	17.45%	24.2%	19.67%
Net Earnings	$1.306B	$7.910B	$973.0M
YoY Change	34.22%	10.18%	-44.3%
Net Earnings / Revenue	1.7%	2.71%	1.4%
Basic Earnings Per Share		$6.00
Diluted Earnings Per Share	$976.1K	$5.95	$740.5K
COMMON SHARES
Basic Shares Outstanding	1.320B shares	1.319B shares	1.309B shares
Diluted Shares Outstanding		1.329B shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.53B	$12.53B	$10.85B
YoY Change	15.4%	15.4%	34.73%
Cash & Equivalents	$9.408B	$9.408B	$7.854B
Short-Term Investments	$3.117B	$3.117B	$3.000B
Other Short-Term Assets	$5.292B	$5.292B	$5.277B
YoY Change	0.28%	0.28%	3.21%
Inventory	$17.76B	$17.76B	$18.50B
Prepaid Expenses
Receivables	$24.43B	$7.932B	$21.74B
Other Receivables	$3.389B	$16.50B	$2.198B
Total Short-Term Assets	$60.01B	$60.01B	$56.37B
YoY Change	6.46%	6.46%	12.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.90B	$32.02B	$12.61B
YoY Change	2.3%	-3.95%	4.67%
Goodwill	$79.12B		$79.55B
YoY Change	-0.54%		-0.25%
Intangibles	$29.03B		$31.14B
YoY Change	-6.79%		-5.98%
Long-Term Investments	$23.03B	$23.03B	$20.81B
YoY Change	10.63%	10.63%	20.2%
Other Assets	$4.714B	$9.801B	$4.624B
YoY Change	1.95%	3.11%	0.52%
Total Long-Term Assets	$173.0B	$173.0B	$174.3B
YoY Change	-0.78%	-0.78%	1.28%
TOTAL ASSETS
Total Short-Term Assets	$60.01B	$60.01B	$56.37B
Total Long-Term Assets	$173.0B	$173.0B	$174.3B
Total Assets	$233.0B	$233.0B	$230.7B
YoY Change	0.99%	0.99%	3.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$38.68B	$38.68B	$34.87B
YoY Change	10.94%	10.94%	12.58%
Accrued Expenses	$17.67B	$19.23B	$14.24B
YoY Change	24.06%	21.63%	17.39%
Deferred Revenue	$87.00M		$71.00M
YoY Change	22.54%		-2.74%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.205B	$4.205B	$5.440B
YoY Change	-22.7%	-22.7%	43.88%
Total Short-Term Liabilities	$67.81B	$67.81B	$62.02B
YoY Change	9.34%	9.34%	16.35%
LONG-TERM LIABILITIES
Long-Term Debt	$51.97B	$51.97B	$59.21B
YoY Change	-12.22%	-12.22%	-8.49%
Other Long-Term Liabilities	$1.904B	$31.57B	$2.351B
YoY Change	-19.01%	-4.32%	8.74%
Total Long-Term Liabilities	$1.904B	$83.54B	$2.351B
YoY Change	-19.01%	-9.39%	-96.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$67.81B	$67.81B	$62.02B
Total Long-Term Liabilities	$1.904B	$83.54B	$2.351B
Total Liabilities	$157.6B	$157.9B	$161.0B
YoY Change	-2.11%	-2.11%	1.73%
SHAREHOLDERS EQUITY
Retained Earnings	$54.91B		$49.64B
YoY Change	10.61%		10.05%
Common Stock	$17.00M		$17.00M
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$28.17B		$28.18B
YoY Change	-0.02%		-0.2%
Treasury Stock Shares	422.0M shares		423.0M shares
Shareholders Equity	$75.08B	$75.08B	$69.39B
YoY Change
Total Liabilities & Shareholders Equity	$233.0B	$233.0B	$230.7B
YoY Change	0.99%	0.99%	3.72%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	$1.306B	$7.910B	$973.0M
YoY Change	34.22%	10.18%	-44.3%
Depreciation, Depletion And Amortization		$4.512B
YoY Change		1.6%
Cash From Operating Activities	$4.005B	$18.27B	$3.567B
YoY Change	12.28%	15.13%	35.42%
INVESTING ACTIVITIES
Capital Expenditures	-$597.0M	$2.520B	-$713.0M
YoY Change	-16.27%	3.41%	25.75%
Acquisitions		$146.0M
YoY Change		-83.14%
Other Investing Activities	-$843.0M	-$122.0M	-$521.0M
YoY Change	61.8%		266.9%
Cash From Investing Activities	-$1.440B	-$5.261B	-$1.234B
YoY Change	16.69%	-4.93%	74.05%
FINANCING ACTIVITIES
Cash Dividend Paid		$2.625B
YoY Change		0.04%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$10.25B
YoY Change		-34.4%
Cash From Financing Activities	-2.831B	-$11.36B	-3.735B
YoY Change	-24.2%	47.56%	159.38%
NET CHANGE
Cash From Operating Activities	4.005B	$18.27B	3.567B
Cash From Investing Activities	-1.440B	-$5.261B	-1.234B
Cash From Financing Activities	-2.831B	-$11.36B	-3.735B
Net Change In Cash	-266.0M	$1.648B	-1.402B
YoY Change	-81.03%	-37.46%	-389.07%
FREE CASH FLOW
Cash From Operating Activities	$4.005B	$18.27B	$3.567B
Capital Expenditures	-$597.0M	$2.520B	-$713.0M
Free Cash Flow	$4.602B	$15.75B	$4.280B
YoY Change	7.52%	17.25%	33.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0000064803
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2019	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations
CY2021Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-01011
CY2021	dei	Entity Registrant Name EntityRegistrantName	CVS HEALTH CORPORATION
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	05-0494040
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	One CVS Drive,
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Woonsocket,
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	RI
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02895
CY2021	dei	City Area Code CityAreaCode	(401)
CY2021	dei	Local Phone Number LocalPhoneNumber	765-1500
CY2021	dei	Trading Symbol TradingSymbol	CVS
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2021	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	109651334285	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1312510426	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	76132000000	USD
CY2020	us-gaap	Premiums Earned Net PremiumsEarnedNet	69364000000	USD
CY2019	us-gaap	Premiums Earned Net PremiumsEarnedNet	63122000000	USD
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	1199000000	USD
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	798000000	USD
CY2019	us-gaap	Net Investment Income NetInvestmentIncome	1011000000	USD
CY2021	us-gaap	Revenues Revenues	292111000000	USD
CY2020	us-gaap	Revenues Revenues	268706000000	USD
CY2019	us-gaap	Revenues Revenues	256776000000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	175803000000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	163981000000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	158719000000	USD
CY2021	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	64260000000	USD
CY2020	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	55679000000	USD
CY2019	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	52529000000	USD
CY2020	cvs	Operating Expenses Excluding Store Impairments And Goodwill Impairments OperatingExpensesExcludingStoreImpairmentsAndGoodwillImpairments	35135000000	USD
CY2021	cvs	Store Impairment Charges StoreImpairmentCharges	1358000000	USD
CY2020	cvs	Store Impairment Charges StoreImpairmentCharges	0	USD
CY2019	cvs	Store Impairment Charges StoreImpairmentCharges	231000000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	431000000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	cvs	Operating Expenses Excluding Store Impairments And Goodwill Impairments OperatingExpensesExcludingStoreImpairmentsAndGoodwillImpairments	37066000000	USD
CY2019	cvs	Operating Expenses Excluding Store Impairments And Goodwill Impairments OperatingExpensesExcludingStoreImpairmentsAndGoodwillImpairments	33310000000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	278918000000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	254795000000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	244789000000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	13193000000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	13911000000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	11987000000	USD
CY2021	us-gaap	Interest Expense InterestExpense	2503000000	USD
CY2020	us-gaap	Interest Expense InterestExpense	2907000000	USD
CY2019	us-gaap	Interest Expense InterestExpense	3035000000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-452000000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1440000000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-79000000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	182000000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	206000000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	124000000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	10420000000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9770000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8997000000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2522000000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2569000000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2366000000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	7898000000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	7201000000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7461000000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7574000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	6631000000	USD
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-9000000	USD
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
CY2021	us-gaap	Profit Loss ProfitLoss	7898000000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	7192000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	6631000000	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12000000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13000000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3000000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	7910000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	7179000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	6634000000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	6.00
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	5.49
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	5.10
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	0
CY2020	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.01
CY2019	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	0
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.00
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.48
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.10
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1319000000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1309000000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1301000000	shares
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.95
CY2020	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.47
CY2019	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.08
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0
CY2020	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.01
CY2019	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.95
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.46
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.08
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1329000000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1314000000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1305000000	shares
CY2021	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.00
CY2020	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.00
CY2019	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.00
CY2021	us-gaap	Profit Loss ProfitLoss	7898000000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	7192000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	6631000000	USD
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-436000000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	440000000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	677000000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	162000000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-26000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-31000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-33000000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-20000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	17000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-111000000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-449000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	395000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	917000000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	7449000000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	7587000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	7548000000	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12000000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13000000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7551000000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9408000000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5292000000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5277000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7854000000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	3117000000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	3000000000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24431000000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21742000000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	17760000000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	18496000000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	60008000000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	56369000000	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	23025000000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	20812000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12896000000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12606000000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19122000000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20729000000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	79121000000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	79552000000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	29026000000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31142000000	USD
CY2021Q4	us-gaap	Separate Account Assets SeparateAccountAssets	5087000000	USD
CY2020Q4	us-gaap	Separate Account Assets SeparateAccountAssets	4881000000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4714000000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4624000000	USD
CY2021Q4	us-gaap	Assets Assets	232999000000	USD
CY2020Q4	us-gaap	Assets Assets	230715000000	USD
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	12544000000	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	11138000000	USD
CY2021Q4	cvs	Pharmacy Claimsand Discounts Payable Current PharmacyClaimsandDiscountsPayableCurrent	17330000000	USD
CY2020Q4	cvs	Pharmacy Claimsand Discounts Payable Current PharmacyClaimsandDiscountsPayableCurrent	15795000000	USD
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	8808000000	USD
CY2020Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	7936000000	USD
CY2021Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	4301000000	USD
CY2020Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	4270000000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17670000000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14243000000	USD
CY2021Q4	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1303000000	USD
CY2020Q4	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1557000000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1646000000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1638000000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	4205000000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	5440000000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	67807000000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62017000000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18177000000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18757000000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	51971000000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	59207000000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6270000000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6794000000	USD
CY2021Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	5087000000	USD
CY2020Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	4881000000	USD
CY2021Q4	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	6402000000	USD
CY2020Q4	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	7007000000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1904000000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2351000000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	157618000000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	161014000000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1744000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1322000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1733000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1310000000	shares
CY2021Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	47377000000	USD
CY2020Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	46513000000	USD
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	422000000	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	423000000	shares
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	28173000000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	28178000000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	54906000000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	49640000000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	965000000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1414000000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	75075000000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	69389000000	USD
CY2021Q4	us-gaap	Minority Interest MinorityInterest	306000000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	312000000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	75381000000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	69701000000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	232999000000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	230715000000	USD
CY2021	us-gaap	Proceeds From Customers ProceedsFromCustomers	284219000000	USD
CY2020	us-gaap	Proceeds From Customers ProceedsFromCustomers	264327000000	USD
CY2019	us-gaap	Proceeds From Customers ProceedsFromCustomers	248393000000	USD
CY2021	cvs	Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies	165783000000	USD
CY2020	cvs	Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies	158636000000	USD
CY2019	cvs	Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies	149655000000	USD
CY2021	cvs	Paymentsfor Insurance Benefits PaymentsforInsuranceBenefits	63598000000	USD
CY2020	cvs	Paymentsfor Insurance Benefits PaymentsforInsuranceBenefits	55124000000	USD
CY2019	cvs	Paymentsfor Insurance Benefits PaymentsforInsuranceBenefits	52242000000	USD
CY2021	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	31652000000	USD
CY2020	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	29763000000	USD
CY2019	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	28932000000	USD
CY2021	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	743000000	USD
CY2020	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	894000000	USD
CY2019	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	955000000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2469000000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	2904000000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2954000000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3195000000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2929000000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2717000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	18265000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	15865000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12848000000	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7246000000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6467000000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7049000000	USD
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	9963000000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	9639000000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	7534000000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2520000000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2437000000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2457000000	USD
CY2021	us-gaap	Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity	0	USD
CY2020	us-gaap	Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity	101000000	USD
CY2019	us-gaap	Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity	5000000	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	146000000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	866000000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	444000000	USD
CY2021	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2020	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	840000000	USD
CY2019	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-122000000	USD
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-42000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5261000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5534000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3339000000	USD
CY2021	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	0	USD
CY2020	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	0	USD
CY2019	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-720000000	USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	987000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9958000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3736000000	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	10254000000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	15631000000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	8336000000	USD
CY2021	us-gaap	Payments For Proceeds From Derivative Instrument Financing Activities PaymentsForProceedsFromDerivativeInstrumentFinancingActivities	0	USD
CY2020	us-gaap	Payments For Proceeds From Derivative Instrument Financing Activities PaymentsForProceedsFromDerivativeInstrumentFinancingActivities	7000000	USD
CY2019	us-gaap	Payments For Proceeds From Derivative Instrument Financing Activities PaymentsForProceedsFromDerivativeInstrumentFinancingActivities	25000000	USD
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	2625000000	USD
CY2020	us-gaap	Payments Of Dividends PaymentsOfDividends	2624000000	USD
CY2019	us-gaap	Payments Of Dividends PaymentsOfDividends	2603000000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	549000000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	264000000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	210000000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	168000000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	88000000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	112000000	USD
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	155000000	USD
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	432000000	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	196000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11356000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7696000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7654000000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1648000000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2635000000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1855000000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11043000000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8408000000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6553000000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12691000000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11043000000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8408000000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	7898000000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	7192000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	6631000000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4512000000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4441000000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4371000000	USD
CY2021	cvs	Store Impairment Charges StoreImpairmentCharges	1358000000	USD
CY2020	cvs	Store Impairment Charges StoreImpairmentCharges	0	USD
CY2019	cvs	Store Impairment Charges StoreImpairmentCharges	231000000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	431000000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	484000000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	400000000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	453000000	USD
CY2021	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	269000000	USD
CY2019	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-205000000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-452000000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1440000000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-79000000	USD
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-428000000	USD
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-570000000	USD
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-654000000	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	390000000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-72000000	USD
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	17000000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17000000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-33000000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2703000000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1510000000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2158000000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-735000000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	973000000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1075000000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3000000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-364000000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	614000000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2898000000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2769000000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3550000000	USD
CY2021	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	169000000	USD
CY2020	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-231000000	USD
CY2019	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	320000000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2852000000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2740000000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1476000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	18265000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	15865000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12848000000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	58543000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	6631000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	917000000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	532000000	USD
CY2019	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	7000000	USD
CY2019	us-gaap	Dividends Common Stock DividendsCommonStock	2615000000	USD
CY2019	cvs	Noncontrollinginterest Other Period Increase Decrease NoncontrollinginterestOtherPeriodIncreaseDecrease	-9000000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64170000000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	7192000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	395000000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	541000000	USD
CY2020	cvs	Espp Issuance Net Of Treasury Stock Value Acquired Cost Method ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod	57000000	USD
CY2020	us-gaap	Dividends Common Stock DividendsCommonStock	2644000000	USD
CY2020	cvs	Noncontrollinginterest Other Period Increase Decrease NoncontrollinginterestOtherPeriodIncreaseDecrease	-7000000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	69701000000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	7898000000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-449000000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	864000000	USD
CY2021	cvs	Espp Issuance Net Of Treasury Stock Value Acquired Cost Method ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod	5000000	USD
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	2644000000	USD
CY2021	cvs	Noncontrollinginterest Other Period Increase Decrease NoncontrollinginterestOtherPeriodIncreaseDecrease	6000000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	75381000000	USD
CY2021Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2019Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2020Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2020Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	USD
CY2019Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	USD
CY2021Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	17000000	USD
CY2021Q4	cvs	Number Of Plan Members NumberOfPlanMembers	110000000	people
CY2021Q4	cvs	Numberof Patients Servedper Year NumberofPatientsServedperYear	1000000	patient
CY2021Q4	cvs	Number Of People Served NumberOfPeopleServed	35000000	people
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	Segment
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div>
CY2021	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9408000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7854000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5683000000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	3065000000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2913000000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2454000000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	218000000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	276000000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	271000000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12691000000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11043000000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8408000000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7932000000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7101000000	USD
CY2021Q4	cvs	Vendorand Manufacturer Receivables VendorandManufacturerReceivables	10573000000	USD
CY2020Q4	cvs	Vendorand Manufacturer Receivables VendorandManufacturerReceivables	9815000000	USD
CY2021Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	2537000000	USD
CY2020Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	2628000000	USD
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3389000000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2198000000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24431000000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21742000000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	339000000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	358000000	USD
CY2021Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	895000000	USD
CY2020Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	546000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33550000000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	31306000000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20654000000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18700000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12896000000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12606000000	USD
CY2021	us-gaap	Depreciation Depreciation	2300000000	USD
CY2020	us-gaap	Depreciation Depreciation	2100000000	USD
CY2019	us-gaap	Depreciation Depreciation	1900000000	USD
CY2020	cvs	Store Impairment Charges StoreImpairmentCharges	0	USD
CY2019	cvs	Store Impairment Charges StoreImpairmentCharges	231000000	USD
CY2020Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2020Q4	us-gaap	Self Insurance Reserve SelfInsuranceReserve	927000000	USD
CY2020	cvs	Assumed Interest Rates On Long Duration Group Life And Long Term Care Contracts AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts	0.051
CY2021	cvs	Assumed Interest Rates On Long Duration Group Life And Long Term Care Contracts AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts	0.051
CY2021	us-gaap	Allocations To Policyholders Policies AllocationsToPolicyholdersPolicies	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policyholders’ Funds</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Policyholders’ funds consist primarily of reserves for pension and annuity investment contracts and customer funds associated with certain health contracts. Reserves for such contracts are equal to cumulative deposits less withdrawals and charges plus interest credited thereon, net of experience-rated adjustments. In 2021, interest rates for pension and annuity investment contracts ranged from 3.5% to 4.8%. In 2020, interest rates for pension and annuity investment contracts ranged from 4.1% to 5.1%. Reserves for contracts subject to experience rating reflect the Company’s rights as well as the rights of policyholders and plan participants. The Company also holds funds for HSAs on behalf of members associated with high deductible health plans. These amounts are held to pay for qualified health care expenses incurred by these members. The HSA balances were approximately $2.9 billion and $2.7 billion at December 31, 2021 and 2020, respectively, and are reflected in other current assets with a corresponding liability in policyholders’ funds. These assets are considered restricted cash for cash flow statement purposes.</span></div>Policyholders’ funds liabilities that are expected to be paid within twelve months from the balance sheet date are classified as current on the consolidated balance sheets. Policyholders’ funds liabilities that are expected to be paid greater than twelve months from the balance sheet date are included in other long-term liabilities on the consolidated balance sheets.
CY2021Q4	cvs	Heath Savings Account Balance HeathSavingsAccountBalance	2900000000	USD
CY2020Q4	cvs	Heath Savings Account Balance HeathSavingsAccountBalance	2700000000	USD
CY2021Q4	us-gaap	Self Insurance Reserve SelfInsuranceReserve	1100000000	USD
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	1199000000	USD
CY2021	us-gaap	Revenues Revenues	292111000000	USD
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	798000000	USD
CY2020	us-gaap	Revenues Revenues	268706000000	USD
CY2019	us-gaap	Net Investment Income NetInvestmentIncome	1011000000	USD
CY2019	us-gaap	Revenues Revenues	256776000000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7932000000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7101000000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	87000000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	73000000	USD
CY2021	cvs	Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance	387000000	USD
CY2020	cvs	Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance	357000000	USD
CY2021	cvs	Contract With Customer Liability Redemption And Breakage ContractWithCustomerLiabilityRedemptionAndBreakage	371000000	USD
CY2020	cvs	Contract With Customer Liability Redemption And Breakage ContractWithCustomerLiabilityRedemptionAndBreakage	359000000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	87000000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000000	USD
CY2021	cvs	Pharmacy Rebate Period PharmacyRebatePeriod	P30D
CY2021	cvs	Health Insurer Fee HealthInsurerFee	0	USD
CY2020	cvs	Health Insurer Fee HealthInsurerFee	1000000000	USD
CY2019	cvs	Health Insurer Fee HealthInsurerFee	0	USD
CY2021	us-gaap	Advertising Expense AdvertisingExpense	523000000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	461000000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	396000000	USD
CY2021Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2020Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2020	cvs	Proceeds From Variable Interest Entity ProceedsFromVariableInterestEntity	183000000	USD
CY2021	cvs	Proceeds From Variable Interest Entity ProceedsFromVariableInterestEntity	183000000	USD
CY2019	cvs	Proceeds From Variable Interest Entity ProceedsFromVariableInterestEntity	183000000	USD
CY2020	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-12000000	USD
CY2020	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-3000000	USD
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-9000000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	3117000000	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	23025000000	USD
CY2021Q4	us-gaap	Investments Investments	26142000000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	3000000000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	20812000000	USD
CY2020Q4	us-gaap	Investments Investments	23812000000	USD
CY2021Q4	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	450000000	USD
CY2020Q4	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	524000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Amortized Cost Net DebtSecuritiesAvailableForSaleAmortizedCostNet	22174000000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1172000000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	106000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	23240000000	USD
CY2020Q4	cvs	Debt Securities Available For Sale Amortized Cost Net DebtSecuritiesAvailableForSaleAmortizedCostNet	19396000000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1803000000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	21188000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q4	cvs	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date Within One Year Amortized Cost Net DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNet	1205000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1218000000	USD
CY2021	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	52000000	USD
CY2020	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	56000000	USD
CY2019	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	32000000	USD
CY2021	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	79000000	USD
CY2020	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	77000000	USD
CY2019	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	96000000	USD
CY2021	cvs	Related Party Transaction Charitable Contribution To Non Profit Entity RelatedPartyTransactionCharitableContributionToNonProfitEntity	50000000	USD
CY2020	cvs	Related Party Transaction Charitable Contribution To Non Profit Entity RelatedPartyTransactionCharitableContributionToNonProfitEntity	50000000	USD
CY2019	cvs	Related Party Transaction Charitable Contribution To Non Profit Entity RelatedPartyTransactionCharitableContributionToNonProfitEntity	30000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date After One Through Five Years Amortized Cost Net DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAmortizedCostNet	6965000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	7142000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Maturity Allocated And Single Maturity Dateafter Five Through Ten Years Amortized Cost Net DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateafterFiveThroughTenYearsAmortizedCostNet	4733000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	4910000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Allocated And Single Maturity Date Maturity After10 Years Amortized Cost Net DebtSecuritiesAvailableForSaleAllocatedAndSingleMaturityDateMaturityAfter10YearsAmortizedCostNet	4332000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	4993000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Amortized Cost Net DebtSecuritiesAvailableForSaleAmortizedCostNet	22174000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	23240000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	3700	security
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	6800000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	84000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	317	security
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	584000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	22000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	4017	security
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	7384000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	106000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	468	security
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	869000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	10000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	59	security
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	46000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	527	security
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	915000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	11000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear	51000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss	1000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears	2242000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss	33000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears	1365000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss	27000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears	462000000	USD
CY2021Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss	10000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	7384000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	106000000	USD
CY2021	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1070000000	USD
CY2020	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	781000000	USD
CY2019	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	854000000	USD
CY2021	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	47000000	USD
CY2020	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	35000000	USD
CY2019	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	42000000	USD
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3572000000	USD
CY2021	cvs	Investment Income Excluding Capital Gainsor Losses InvestmentIncomeExcludingCapitalGainsorLosses	1023000000	USD
CY2020	cvs	Investment Income Excluding Capital Gainsor Losses InvestmentIncomeExcludingCapitalGainsorLosses	746000000	USD
CY2019	cvs	Investment Income Excluding Capital Gainsor Losses InvestmentIncomeExcludingCapitalGainsorLosses	812000000	USD
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	176000000	USD
CY2020	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	52000000	USD
CY2019	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	199000000	USD
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	1199000000	USD
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	798000000	USD
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	1011000000	USD
CY2021Q4	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	-42000000	USD
CY2020Q4	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	-49000000	USD
CY2021Q4	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	USD
CY2020Q4	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	USD
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	-24000000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3913000000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	4773000000	USD
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	72000000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	80000000	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	146000000	USD
CY2021	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	-14000000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	-62000000	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	-17000000	USD
CY2021	us-gaap	Fair Value Asset Recurring Basis Still Held Unrealized Gain Loss Oci FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci	-4000000	USD
CY2020	us-gaap	Fair Value Asset Recurring Basis Still Held Unrealized Gain Loss Oci FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci	-4000000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	79749000000	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	308000000	USD
CY2020	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	505000000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	79552000000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	431000000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	79121000000	USD
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6600000000	USD
CY2020Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6100000000	USD
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	10498000000	USD
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	10498000000	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	41753000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12727000000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	29026000000	USD
CY2021	us-gaap	Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension	P15Y3M18D
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	10498000000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	10498000000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	41623000000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10481000000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31142000000	USD
CY2020	us-gaap	Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension	P15Y2M12D
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2300000000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2300000000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1858000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1826000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1785000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1734000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1494000000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2633000000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2670000000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	2720000000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	62000000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	56000000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	38000000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	62000000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	58000000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	44000000	USD
CY2021	cvs	Finance Lease Cost FinanceLeaseCost	124000000	USD
CY2020	cvs	Finance Lease Cost FinanceLeaseCost	114000000	USD
CY2019	cvs	Finance Lease Cost FinanceLeaseCost	82000000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	25000000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	22000000	USD
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	24000000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	604000000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	599000000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	581000000	USD
CY2021	us-gaap	Sublease Income SubleaseIncome	59000000	USD
CY2020	us-gaap	Sublease Income SubleaseIncome	55000000	USD
CY2019	us-gaap	Sublease Income SubleaseIncome	50000000	USD
CY2021	us-gaap	Lease Cost LeaseCost	3327000000	USD
CY2020	us-gaap	Lease Cost LeaseCost	3350000000	USD
CY2019	us-gaap	Lease Cost LeaseCost	3357000000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	2714000000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	2724000000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	2701000000	USD
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	62000000	USD
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	58000000	USD
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	44000000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	50000000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	34000000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	26000000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1254000000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1679000000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1824000000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	278000000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	313000000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	283000000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19122000000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20729000000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1646000000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1638000000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18177000000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18757000000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	19823000000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	20395000000	USD
CY2021Q4	cvs	Finance Lease Right Of Use Asset Gross FinanceLeaseRightOfUseAssetGross	1375000000	USD
CY2020Q4	cvs	Finance Lease Right Of Use Asset Gross FinanceLeaseRightOfUseAssetGross	1107000000	USD
CY2021Q4	cvs	Finance Lease Right Of Use Asset Accumulated Depreciation FinanceLeaseRightOfUseAssetAccumulatedDepreciation	188000000	USD
CY2020Q4	cvs	Finance Lease Right Of Use Asset Accumulated Depreciation FinanceLeaseRightOfUseAssetAccumulatedDepreciation	106000000	USD
CY2021Q4	cvs	Finance Lease Right Of Use Asset Net FinanceLeaseRightOfUseAssetNet	1187000000	USD
CY2020Q4	cvs	Finance Lease Right Of Use Asset Net FinanceLeaseRightOfUseAssetNet	1001000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	50000000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	33000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1250000000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1050000000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1300000000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1083000000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y9M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P13Y3M18D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P20Y
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P20Y3M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.044
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.050
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.056
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	122000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2685000000	USD
CY2021Q4	cvs	Lessee Liability Payments Year One LesseeLiabilityPaymentsYearOne	2807000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	121000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2613000000	USD
CY2021Q4	cvs	Lessee Liability Payments Due Year Two LesseeLiabilityPaymentsDueYearTwo	2734000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	111000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2398000000	USD
CY2021Q4	cvs	Lessee Liability Payments Due Year Three LesseeLiabilityPaymentsDueYearThree	2509000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	110000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2217000000	USD
CY2021Q4	cvs	Lessee Liability Payments Due Year Four LesseeLiabilityPaymentsDueYearFour	2327000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	109000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2054000000	USD
CY2021Q4	cvs	Lessee Liability Payments Due Year Five LesseeLiabilityPaymentsDueYearFive	2163000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	1495000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	14103000000	USD
CY2021Q4	cvs	Lessee Liability Payments Due After Year Five LesseeLiabilityPaymentsDueAfterYearFive	15598000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	2068000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	26070000000	USD
CY2021Q4	cvs	Lessee Liability Payments Due LesseeLiabilityPaymentsDue	28138000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	768000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6247000000	USD
CY2021Q4	cvs	Lessee Liability Undiscounted Excess Amount LesseeLiabilityUndiscountedExcessAmount	7015000000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1300000000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	19823000000	USD
CY2021Q4	cvs	Lease Liability LeaseLiability	21123000000	USD
CY2021Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	311000000	USD
CY2021Q4	cvs	Operating And Capital Leases Amount Due In Excess Of Remaining Estimated Economic Life OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife	2400000000	USD
CY2020	us-gaap	Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity	101000000	USD
CY2019	us-gaap	Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity	5000000	USD
CY2020	us-gaap	Sale And Leaseback Transaction Gain Loss Net SaleAndLeasebackTransactionGainLossNet	3000000	USD
CY2019	us-gaap	Sale And Leaseback Transaction Gain Loss Net SaleAndLeasebackTransactionGainLossNet	0	USD
CY2019	cvs	Store Impairment Charges StoreImpairmentCharges	231000000	USD
CY2021	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the December 31, 2021 health care net incurred and paid claims development tables to the health care costs payable liability on the consolidated balance sheet is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-duration health care costs payable, net of reinsurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,574 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total health care costs payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,808 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1300000000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1083000000	USD
CY2021Q4	cvs	Longterm Debt Gross And Lease Obligation LongtermDebtGrossAndLeaseObligation	56743000000	USD
CY2020Q4	cvs	Longterm Debt Gross And Lease Obligation LongtermDebtGrossAndLeaseObligation	65318000000	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	219000000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	238000000	USD
CY2021Q4	cvs	Debt Instrument Unamortized Discountand Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet	786000000	USD
CY2020Q4	cvs	Debt Instrument Unamortized Discountand Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet	909000000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	56176000000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	64647000000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	4205000000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	5440000000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	51971000000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	59207000000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	4154000000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1719000000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2706000000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3785000000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	2507000000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	40572000000	USD
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	55443000000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1300000000	USD
CY2021Q4	cvs	Longterm Debt Gross And Lease Obligation LongtermDebtGrossAndLeaseObligation	56743000000	USD
CY2021Q4	us-gaap	Federal Home Loan Bank Advances General Debt Obligations Disclosures Maximum Amount Available FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable	995000000	USD
CY2021Q3	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	987000000	USD
CY2020Q3	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	3970000000	USD
CY2020Q1	us-gaap	Payments For Proceeds From Derivative Instrument Financing Activities PaymentsForProceedsFromDerivativeInstrumentFinancingActivities	7000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-5000000	USD
CY2021Q4	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-80000000	USD
CY2021Q4	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	8000000	USD
CY2021Q4	cvs	Debt Extinguishment Fees DebtExtinguishmentFees	1000000	USD
CY2021Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-89000000	USD
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-332000000	USD
CY2021Q3	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	26000000	USD
CY2021Q3	cvs	Debt Extinguishment Fees DebtExtinguishmentFees	5000000	USD
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-363000000	USD
CY2020Q4	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-619000000	USD
CY2020Q4	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	45000000	USD
CY2020Q4	cvs	Debt Extinguishment Fees DebtExtinguishmentFees	10000000	USD
CY2020Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-674000000	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-706000000	USD
CY2020Q3	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	47000000	USD
CY2020Q3	cvs	Debt Extinguishment Fees DebtExtinguishmentFees	13000000	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-766000000	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-76000000	USD
CY2019Q3	cvs	Debt Extinguishment Fees DebtExtinguishmentFees	8000000	USD
CY2019Q3	cvs	Net Gain From Write Off Of Deferred Debt Issuance Costs NetGainFromWriteOffOfDeferredDebtIssuanceCosts	5000000	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-79000000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	552000000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	520000000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	550000000	USD
CY2020	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.029
CY2019	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.040
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.048
CY2020	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.063
CY2021Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.028
CY2020Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.025
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.018
CY2019	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.065
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2285000000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2615000000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	518000000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2450000000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	665000000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	565000000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2950000000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3133000000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3015000000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-306000000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-450000000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-535000000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-122000000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-114000000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-114000000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-428000000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-564000000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-649000000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2522000000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2569000000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2366000000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.032
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.040
CY2021	cvs	Health Insurer Fee Tax Effect Percent HealthInsurerFeeTaxEffectPercent	0
CY2020	cvs	Health Insurer Fee Tax Effect Percent HealthInsurerFeeTaxEffectPercent	0.022
CY2019	cvs	Health Insurer Fee Tax Effect Percent HealthInsurerFeeTaxEffectPercent	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	-0.012
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Domestic EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic	-0.012
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Domestic EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Domestic EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.011
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.013
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.242
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.263
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.263
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	5563000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	5742000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	99000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	80000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	193000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	238000000	USD
CY2021Q4	cvs	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Bad Debts And Other Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances	489000000	USD
CY2020Q4	cvs	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Bad Debts And Other Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances	395000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	416000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	568000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	78000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	43000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	501000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	489000000	USD
CY2021Q4	cvs	Deferred Tax Assets Payroll Tax Deferral DeferredTaxAssetsPayrollTaxDeferral	87000000	USD
CY2020Q4	cvs	Deferred Tax Assets Payroll Tax Deferral DeferredTaxAssetsPayrollTaxDeferral	173000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	396000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	500000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	325000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	454000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7497000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7774000000	USD
CY2021Q4	cvs	Deferred Tax Liabilities Retirement Benefits DeferredTaxLiabilitiesRetirementBenefits	105000000	USD
CY2020Q4	cvs	Deferred Tax Liabilities Retirement Benefits DeferredTaxLiabilitiesRetirementBenefits	29000000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	334000000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	421000000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	4947000000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	5368000000	USD
CY2021Q4	cvs	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	8381000000	USD
CY2020Q4	cvs	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	8750000000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13767000000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14568000000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6270000000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6794000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	416000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	325000000	USD
CY2021Q2	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.50
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2000000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	768000000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	655000000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	661000000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3000000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4000000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	52000000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	182000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	115000000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	33000000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	56000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	111000000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	7000000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	7000000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	14000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	7000000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	782000000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	768000000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	655000000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	40000000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	34000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	49000000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	151000000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	121000000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	669000000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	484000000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	400000000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	453000000	USD
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	3000000	shares
CY2021	cvs	Stock Issued During Period Employee Stock Purchase Plan Average Purchase Priceof Shares Purchased StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased	60.51
CY2020Q3	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.50
CY2020Q1	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.50
CY2020Q4	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.50
CY2020Q2	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.50
CY2021Q3	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.50
CY2021Q1	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.50
CY2021Q4	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.50
CY2021Q4	cvs	Dividends Payable Quarterly Dividends Declared Increase Amount Percent DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent	0.10
CY2021Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	7261000000	USD
CY2021Q4	us-gaap	Assets Held By Insurance Regulators AssetsHeldByInsuranceRegulators	794000000	USD
CY2021Q4	us-gaap	Statutory Accounting Practices Statutory Amount Available For Dividend Payments Without Regulatory Approval StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval	2939000000	USD
CY2021Q4	us-gaap	Minority Interest MinorityInterest	306000000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	312000000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-449000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	395000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	917000000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	7898000000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	7201000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	6631000000	USD
CY2021	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	0	USD
CY2020	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	0	USD
CY2019	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	5000000	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12000000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13000000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3000000	USD
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	7910000000	USD
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	7188000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	6629000000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1319000000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1309000000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1301000000	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	10000000	shares
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	5000000	shares
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	4000000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1329000000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1314000000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1305000000	shares
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	6.00
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	5.49
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	5.10
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.95
CY2020	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.47
CY2019	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.08
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2436000000	USD
CY2021Q4	us-gaap	Reinsurance Recoverables On Paid And Unpaid Losses ReinsuranceRecoverablesOnPaidAndUnpaidLosses	2549000000	USD
CY2020Q4	us-gaap	Reinsurance Recoverables On Paid And Unpaid Losses ReinsuranceRecoverablesOnPaidAndUnpaidLosses	3055000000	USD
CY2021	us-gaap	Direct Premiums Earned DirectPremiumsEarned	76320000000	USD
CY2020	us-gaap	Direct Premiums Earned DirectPremiumsEarned	69711000000	USD
CY2019	us-gaap	Direct Premiums Earned DirectPremiumsEarned	62968000000	USD
CY2021	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned	492000000	USD
CY2020	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned	478000000	USD
CY2019	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned	2108000000	USD
CY2021	us-gaap	Ceded Premiums Earned CededPremiumsEarned	680000000	USD
CY2020	us-gaap	Ceded Premiums Earned CededPremiumsEarned	825000000	USD
CY2019	us-gaap	Ceded Premiums Earned CededPremiumsEarned	1954000000	USD
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	76132000000	USD
CY2020	us-gaap	Premiums Earned Net PremiumsEarnedNet	69364000000	USD
CY2019	us-gaap	Premiums Earned Net PremiumsEarnedNet	63122000000	USD
CY2021	us-gaap	Policyholder Benefits And Claims Incurred Gross PolicyholderBenefitsAndClaimsIncurredGross	64414000000	USD
CY2020	us-gaap	Policyholder Benefits And Claims Incurred Gross PolicyholderBenefitsAndClaimsIncurredGross	56077000000	USD
CY2019	us-gaap	Policyholder Benefits And Claims Incurred Gross PolicyholderBenefitsAndClaimsIncurredGross	52592000000	USD
CY2021	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	398000000	USD
CY2020	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	329000000	USD
CY2019	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	1562000000	USD
CY2021	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	552000000	USD
CY2020	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	727000000	USD
CY2019	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	1625000000	USD
CY2021	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	64260000000	USD
CY2020	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	55679000000	USD
CY2019	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	52529000000	USD
CY2021Q4	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	250000000	USD
CY2021Q4	cvs	Contractual Obligations To Maintain Levels Of Separate Accounts ContractualObligationsToMaintainLevelsOfSeparateAccounts	1300000000	USD
CY2020Q4	cvs	Contractual Obligations To Maintain Levels Of Separate Accounts ContractualObligationsToMaintainLevelsOfSeparateAccounts	1400000000	USD
CY2021Q4	cvs	Guarantor Obligations Numberof Leases GuarantorObligationsNumberofLeases	72	lease
CY2012	cvs	Loss Contingency Audit Methodology Sample Size LossContingencyAuditMethodologySampleSize	200	member
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	Segment
CY2021	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	290912000000	USD
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	1199000000	USD
CY2021	us-gaap	Revenues Revenues	292111000000	USD
CY2021	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	17312000000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4512000000	USD
CY2020	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	267908000000	USD
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	798000000	USD
CY2020	us-gaap	Revenues Revenues	268706000000	USD
CY2020	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	16008000000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4441000000	USD
CY2019	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	255765000000	USD
CY2019	us-gaap	Net Investment Income NetInvestmentIncome	1011000000	USD
CY2019	us-gaap	Revenues Revenues	256776000000	USD
CY2019	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	15339000000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4371000000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	13193000000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	13911000000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	11987000000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2259000000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2341000000	USD
CY2021	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	132000000	USD
CY2020	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	332000000	USD
CY2019	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	480000000	USD
CY2021	cvs	Store Impairment Charges StoreImpairmentCharges	1358000000	USD
CY2020	cvs	Store Impairment Charges StoreImpairmentCharges	0	USD
CY2019	cvs	Store Impairment Charges StoreImpairmentCharges	231000000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	431000000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	cvs	Business Combination Purchase Price Adjustment Outside Of Measurement Period BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod	-61000000	USD
CY2020	cvs	Business Combination Purchase Price Adjustment Outside Of Measurement Period BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod	0	USD
CY2019	cvs	Business Combination Purchase Price Adjustment Outside Of Measurement Period BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod	0	USD
CY2021	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	269000000	USD
CY2019	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-205000000	USD
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	USD
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	307000000	USD
CY2019	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	USD
CY2021	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	17312000000	USD
CY2020	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	16008000000	USD
CY2019	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	15339000000	USD
CY2021	cvs	Number Of Stores Planned Closure NumberOfStoresPlannedClosure	900	store
CY2019	cvs	Number Of Stores Planned Closure NumberOfStoresPlannedClosure	68	store
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts

Files In Submission

Name	View Source	Status
0000064803-22-000008-index-headers.html	Edgar Link	pending
0000064803-22-000008-index.html	Edgar Link	pending
0000064803-22-000008.txt	Edgar Link	pending
0000064803-22-000008-xbrl.zip	Edgar Link	pending
cvs-20211231.htm	Edgar Link	pending
cvs-20211231.xsd	Edgar Link	pending
cvs-20211231_cal.xml	Edgar Link	unprocessable
cvs-20211231_def.xml	Edgar Link	unprocessable
cvs-20211231_g1.jpg	Edgar Link	pending
cvs-20211231_g2.jpg	Edgar Link	pending
cvs-20211231_htm.xml	Edgar Link	completed
cvs-20211231_lab.xml	Edgar Link	unprocessable
cvs-20211231_pre.xml	Edgar Link	unprocessable
cvshealthlogo1.jpg	Edgar Link	pending
cvshealthlogob.jpg	Edgar Link	pending
exhibit1010-2021.htm	Edgar Link	pending
exhibit1025-2021.htm	Edgar Link	pending
exhibit1055-2021.htm	Edgar Link	pending
exhibit211-2021.htm	Edgar Link	pending
exhibit231-2021.htm	Edgar Link	pending
exhibit311-2021.htm	Edgar Link	pending
exhibit312-2021.htm	Edgar Link	pending
exhibit321-2021.htm	Edgar Link	pending
exhibit322-2021.htm	Edgar Link	pending
exhibit423-2021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVS
CVS Health Corp Stock $cvs

2021 Q4 Form 10-K Financial Statement

#000006480322000008 Filed on February 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS CVS Health Corp Stock $cvs

2021 Q4 Form 10-K Financial Statement

#000006480322000008 Filed on February 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS
CVS Health Corp Stock $cvs